Side by side
How the two compare across structure, mechanism studied, evidence and regulatory status, based on published research.
| Property | Cagrilintide | Semaglutide |
|---|---|---|
| Class | Amylin analogue (amylin & calcitonin receptor agonist) | GLP-1 receptor agonist |
| Research category | obesity and satiety | type 2 diabetes and obesity |
| Evidence level | Moderate | High |
| Overall status | Not approved — phase 3 clinical research | Approved (Rx) — type 2 diabetes, weight management and CV risk reduction |
| FDA | Not approved | Approved (Rx) |
| EMA | Not approved | Approved (Rx) |
| WADA | Check current list | Not listed — check current list |
| Mechanism studied | Cagrilintide → AMY & calcitonin receptors → Hindbrain satiety signalling → Food-intake endpoints | Semaglutide → GLP-1 receptor → Insulin, glucagon & satiety → Weight & glucose endpoints |
| Molecular weight | 4,409 g/mol | 4,113.6 g/mol |
| Sizes in stock | 10mg | Not currently listed |
Where the research overlaps
Both compounds are studied within Metabolic & GLP-1 research. Cagrilintide is classed as amylin analogue (amylin & calcitonin receptor agonist), while Semaglutide is glp-1 receptor agonist. Evidence is rated moderate for Cagrilintide and high for Semaglutide.
For a full write-up, read Amylin Analogues: Pramlintide and Cagrilintide Reviewed.
FOR RESEARCH USE ONLY.Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.